Anti inflammatory Drug Pirfenidone Materials

Anti-inflammatory Drug Pirfenidone CAS 53179-13-8 Pharmaceutical Raws Product Name: Pirfenidone Synonyms: 5-methyl-1-phenyl-2(1h)-pyridon;amr-69;PIRFENIDONE;5-METHYL-1-PHENYL-1H-PYRIDIN-2-ONE;5-METHYL-1-PHENYL-2(1H)-PYRIDINONE;5-METHYL-1-PHENYL-2-(1H)-PYRIDONE;5-Methyl-N-phenyl-2-1H-pyridone;Pirfenidone also see 5-Methyl-1-Phenyl-2(1H)-Pyridinone CAS: 53179-13-8 MF: C12H11NO MW: 185.22 Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease. Pirfenidone Clinical application 1. Idiopathic pulmonary fibrosis degeneration Idiopathic pulmonary fibrosis (IPF) is an unexplained, poor prognosis and high-mortality chronic inflammatory interstitial lung disease. At the same time, PFD is an anti-inflammatory, anti-fibrotic agent which can be used for the treatment of IPF. 2. Liver Fibrosis 3. Renal fibrosis disease 4. Multiple Sclerosis Multiple sclerosis (MS) is a central nervous system-related and the immune-related inflammation and demyelinating diseases. Immune factors relating to it are activation of stellate cells, glial cell, and endothelial cell and the increase of lymphocytes, while PDF have effects of inhibiting the cell activation. 5. Myocardial fibrosis Cardiovascular diseases such as hypertension, cardiomyopathy, and atrial fibrillation can all lead to myocardial fibrosis, thereby resulting in the disease progression or development. Using PDF for treatment of cardiomyopathy caused by Duchenne muscular dystrophy can inhibit myocardial fibrosis, improve the cardiac function. PFD can reduce the incidence of atrial fibrillation and myocardial remodeling through inhibiting fibrosis. 6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas. 7. Prevention of fibrosis after the organ transplant. 8. Rheumatoid arthritis. Welcome to contact: Skype: rdy705 nutrition@chembj.com WhatsApp: +8618578209860 url:http://www.nutritionraws.com